Background
==========

A 15-year old female patient presented with a case of with eosinophilic pneumonia. Development of chronic eosinophilic pneumonia ([Figure 1](#f1-amjcaserep-20-822){ref-type="fig"}) in childhood is a rare phenomenon. We tried to analyze the immunological mechanism involved in the development of eosinophilic pneumonia. Eosinophilic pneumonia is recognized both as an eosinophil-associated disease as well as bronchial asthma. It is obvious that in eosinophilic pneumonia the site of eosinophilic infiltration is mainly the alveolus and the peripheral airway; the disability of pulmonary function is restrictive, as opposed to that of bronchial asthma, which has a relatively central side bronchus region and obstructive function. However, the antigen of eosinophilic pneumonia is still unknown, unlike bronchial asthma. Eosinophil- and T-lymphocyte-activated parameters such as ECP, CD4HLADR/CD4 (%), CD4CD25/CD4 (%), and IL-5 are the immunological factors usually discussednot only in the context of bronchial asthma \[[@b1-amjcaserep-20-822]\] but also in eosinophilic pneumonia \[[@b2-amjcaserep-20-822],[@b3-amjcaserep-20-822]\].

Case Report
===========

Chronic eosinophilic pneumonia during childhood is very rare \[[@b4-amjcaserep-20-822]\]. In December 1997, a 15-year-old girl with chronic refractory pneumonia was referred to Habikino Hospital for evaluation of respiratory distress, dry cough, high temperature, chest pain, pulmonary infiltration, and peripheral eosinophilia. In our hospital, she was diagnosed as having chronic eosinophilic pneumonia for the first time by eosinophilia both in bronchial alveolar lavage fluid (BALF) and in peripheral blood, and eosinophils mainly infiltrated the alveolus region, as shown by fiberscope biopsy. A report of laboratory investigations done on the patient is summarized in [Table 1](#t1-amjcaserep-20-822){ref-type="table"}.

Clinical symptoms of eosinophilic pneumonia including increased body temperature, chest pain and dry cough were observed when the patient was admitted to the hospital. Laboratory investigations showed an increase in blood sedimentation rate (BSR). Serological testing ([Table 1](#t1-amjcaserep-20-822){ref-type="table"}) results for sedimentation antibody of hypersensitivity pneumonia were all negative. Forced vital capacity (FVC) was found to be decreased and showed a restrictive pattern (%FVC; 39%) in spirometry.

Radiographic examinations ([Figure 1](#f1-amjcaserep-20-822){ref-type="fig"}) of recurrence showed a peripheral infiltration wandering shadow, which is characteristic of chronic eosinophilic pneumonia on plain chest radiograph and a computed tomography scan of the chest. The culture tests of BALF and sputum showed that they were negative. Trans-bronchial biopsy demonstrated intra-alveolar infiltration of eosinophils and interstitial infiltration of both eosinophils and lymphocytes. These features were consistent with the diagnosis of chronic eosinophilic pneumonia.

[Figures 2](#f2-amjcaserep-20-822){ref-type="fig"} and [3](#f3-amjcaserep-20-822){ref-type="fig"} represent the parameters examined in activated T-cells and eosinophils.

Mononuclear cells from venous blood and BALF were double-stained using IgG monoclonal antibodies and analyzed by flow cytometry (FACScan, Becton-Dickinson, CA, USA). Concentrations of soluble interleukin 2 receptor in serum and BALF were measured by enzyme-linked immunoabsorbent assay (ELISA) using a commercially available kit (Cytoscreen, CA, USA). Concentrations of IL-5 in the serum and BALF were also measured by an ELISA current phase (Human IL-5 immunoassay, R and D Systems, MN, USA). Concentrations of ECP in serum and BALF were measured by Pharmacia CAP system ECP fluorescent immunoassay (FEIA, Pharmacia Diagnostics AB, Sweden). Changes in %FVC and forced expiratory volume/1 second (FEV1.0%) in the recurrence of the disease are shown in [Table 2](#t2-amjcaserep-20-822){ref-type="table"} and [Figure 4](#f4-amjcaserep-20-822){ref-type="fig"}.

Changed data of %FVC and FEV1.0% on recurrence are shown in [Table 2](#t2-amjcaserep-20-822){ref-type="table"} and [Figure 4](#f4-amjcaserep-20-822){ref-type="fig"}.

Percent FVC and FEV1.0% \[[@b4-amjcaserep-20-822]\] was measured using a portable spirometer (Microspiro HI-601, NIHON-KPHDEN COPOLATION, Tokyo Japan). Data of %FVC changed slightly over time. The percent FVC measurement obtained using non-invasive methods like spirometry was taken as an indicator of her condition. On admission with eosinophilic pneumonia, her %FVC was extremely low (39%), and we thought that non-invasive spirometry testing could be used as a parameter for recurrence. There was an initial remission followed by a decrease in %FVC to values below 100%, indicating the disease recurrence. FEV1 also responded, so the patient might have had a slight tendency to bronchial asthma.

[Table 3](#t3-amjcaserep-20-822){ref-type="table"} shows 12 recurrences of eosinophilic pneumonia.

To control eosinophilic pneumonia, 5 different dosages of inhaled steroids were tried, chosen to avoid adverse effects due to long-term systemic administration of steroids. The controller (ICS) became a single use of steroid inhalation therapy, but several months later, the recurrence of eosinophilic pneumonia symptoms often appear. However systemic treatment using predonine can easily control the disease, and the laboratory data and clinical symptoms showed improvement.

Discussion
==========

General (non-specific) inflammation parameters are listed in [Table 1](#t1-amjcaserep-20-822){ref-type="table"}.

ESR, CRP, and percentage eosinophils were found to be increased in the peripheral blood of the patient. Spirometry showed a forced pattern typical of eosinophilic pneumonia, as shown by an extreme decrease in %FVC. Decreased %FVC may be attributed to an increased accumulation of inflammatory cells, which differs from obstructive dysfunction of bronchial asthma.

Before steroid therapy, eosinophils increased in both BALF (65%) and peripheral blood (33%). An increased expression of HLADR was seen in CD4-positive T-lymphocytes in BALF (62.8%) as compared to that in peripheral blood (6.4%). The expression of CD25 was also found to be increased in CD4-positive T-lymphocytes in BALF (25.5%) compared to peripheral blood (15.5%). The expression of CD25 in CD8-positive T-lymphocytes was almost equal in BALF and peripheral blood. Even in the active phase of bronchial asthma, HLADRCD4/CD4 and CD25CD4/CD4 increased by several percent (1); however, in eosinophilic pneumonia, they increased by at least 10 percent, showing the extremely high levels of inflammation in eosinophilic pneumonia.

In peripheral blood, soluble interleukin 2 receptor concentration (3963 IU/ml) on admission decreased to 1553 IU/ml in remission phase and then increased again to 2504 IU/ml in recurrent phase. In BALF, the concentration of soluble interleukin 2 receptor was below 250 IU/ml during the active phase. Similarly, the concentration of ECP decreased from 206.6 mcg/ml in the active phase to 26.4 mcg/ml in the remission phase and then increased again to 139.1 mcg/ml during the recurrent phase in peripheral blood. The concentration of ECP in BALF was 20.4 mcg/ml. The concentration of interleukin 5 increased to 16.9 pg/ml only in BALF. The concentration of interleukin 5 in peripheral blood was under 7.8 pg/ml.

It is obvious that the T-lymphocyte activation parameters (CD4HLADR/CD4 (%), CD4CD25/CD4 (%) and IL5), also considered as eosinophil-associated activation parameters, increased in BALF more than in peripheral blood. The concentrations of soluble interleukin 2 receptor and ECP in peripheral blood during the active phase were higher than that in BALF ([Figure 3](#f3-amjcaserep-20-822){ref-type="fig"}). The low values given by volume unit such as ECP and soluble interleukin 2 receptor could not be evaluated due to dilution of normal saline using BALF. On the other hand, the concentration of soluble interleukin 2 receptor increases during malignant diseases \[[@b5-amjcaserep-20-822]\] and decreases during eosinophil-related diseases. The concentrations of both soluble interleukin 2 receptor and ECP \[[@b6-amjcaserep-20-822]\] in peripheral blood are reflective of eosinophilic pneumonia. The real results of ECP, IL-5, and soluble interleukin 2 receptor in peripheral tissue should be higher. Eosinophil-related activation parameters are activated in the peripheral airway in chronic eosinophilic pneumonia. By accidental inhalation, antigens that are smaller than asthmatic antigens reach peripheral airways and may cause chronic eosinophilic pneumonia.

Pulmonary function in eosinophilic pneumonia
--------------------------------------------

In this study, %FVC is recognized as a parameter for eosinophilic pneumonia. In fact, change in %FVC was observed along with clinical symptoms like a rise in temperature, chest pain, and respiratory distress, change in percentage of eosinophil in peripheral blood and altered BSR. Sveinsson et al. \[[@b7-amjcaserep-20-822]\] previously reported that FEV1 and %FVC are decreased in eosinophilic pneumonia. In this study, it was observed that %FVC had a relationship with other clinical and laboratory parameters but not with FEV1%. As compared to other parameters, %FVC offers various advantages in prediction of chronic eosinophilia. The procedure to determine %FVC is non-invasive, quick, less expensive, and less laborious. This is the first study in which %FVC was used as a parameter for predicting eosinophilic pneumonia and in which the disease recurrences were managed using ICS treatments.

Inhaled steroid in eosinophilic pneumonia
-----------------------------------------

Our results show that activated T-cells and eosinophilic inflammation existed mainly in peripheral airways rather than in peripheral blood. We considered that inhaled steroid is useful \[[@b8-amjcaserep-20-822]\] for treating peripheral airway inflammation in chronic eosinophilic pneumonia. But other group considered inhaled steroids not effective \[[@b8-amjcaserep-20-822]\]. Chan et al. \[[@b9-amjcaserep-20-822]\] reported a patient who underwent treatment with systemic corticosteroids followed by inhaled steroids and who remained in remission for 2 years. We tried 5 kinds of inhaled steroids during the active and the remission phases of eosinophilic pneumonia to avoid the adverse effects associated with systemic administration of steroids, but we could not achieve sufficient efficacy using inhaled steroids. A roentgen photograph ([Figure 1](#f1-amjcaserep-20-822){ref-type="fig"}) showed a borderless, cloudy, and wandering shadow-like appearance of the peripheral lung area. Pulmonary function of eosinophilic pneumonia showed a restrictive pattern. Single use of ICSs could not control the persistence of remission. Three reasons may have contributed to the lack of response. Firstly, the particle size of the inhaled steroid was large and hence could not reach the inflammation region and peripheral lung area, whereas Qval (Beclomethasone, pMDI) releases super-small aerosol (diameter 1.1 µm). The second reason could be the weak anti-inflammatory effect of inhaled steroids themselves. As seen in the roentgen image, the bronchus might be closed by the accumulation of inflammatory cells. Inhaled steroids with smaller particle size \[[@b10-amjcaserep-20-822]\] and strong anti-inflammatory effects are needed for the treatment of eosinophilic pneumonia.

Conclusions
===========

Our T-cell activation parameter data (HLADRCD4/CD4 percentages and CD25CD4/CD4 percentages) and eosinophil activation parameter data (IL-5) showed higher levels in BALF than in peripheral blood. The values were higher during the active phase than during the remission phase in the peripheral blood.

The principal inflammation region of eosinophilic pneumonia is considered to be in the peripheral bronchus and in the alveoli. Accordingly, inhaled steroids were considered effective to control eosinophilic pneumonia, but 5 kinds of ICS were not effective to maintain the remission of the disease. Determination of %FVC was useful to predict the recurrence of the disease.
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FVC

:   forced vital capacity;

FEV1.0

:   forced expiratory volume;

ICS

:   inhaled corticosteroid

![Roentgen photograph. Roentgen photograph shows a borderless, cloudy, wandering shadow-like appearance of the peripheral lung area. Pulmonary function of eosinophilic pneumonia showed a restrictive pattern, indicating that the drug in its aerosol form cannot reach the peripheral lung area. This may be the reason for the ineffectiveness of the inhaled steroids.](amjcaserep-20-822-g001){#f1-amjcaserep-20-822}

![Eosinophil (%), CD4HLADR/CD4 (%), and CD4CD25/CD4 (%). Figure shows the changes of eosinophil (%), CD4HLADR/CD4 (%), and CD4CD25/CD4 (%) on remission, recurrence, and active phase. During all these phases, the level of each of these factors was higher in BALF than in peripheral blood. This phenomenon indicates that higher levels inflammation existed in BALF than in peripheral blood.](amjcaserep-20-822-g002){#f2-amjcaserep-20-822}

![sIL2R, ECP, and IL5. Although the level of IL5 was higher than the other factors, the levels of sIL2R and ECP were not higher in BALF than that in the peripheral blood. These results seem strange and we have no explanation for this phenomenon.](amjcaserep-20-822-g003){#f3-amjcaserep-20-822}

![%FVC and FEV1 on recurrence. An extreme decrease in %FVC was seen when the disease recurred. We thought that non-invasive spirometry test could be a parameter for recurrence. FEV1 also responded, so the patient might have had tendency to bronchial asthma.](amjcaserep-20-822-g004){#f4-amjcaserep-20-822}

###### 

Data on admission. On admission, clinical symptoms of eosinophilic pneumonia like rise in temperature, chest pain, and dry cough appeared. An increase in BSR was observed during laboratory investigations and a restrictive pattern with decrease in %FVC was observed during spirometry.

  **Blood cell**          **Inflammatory data**    **Immunoglobulin**
  ----------------------- ------------------------ ------------------------
  WBC 13000/mm^3^         ESR 110 mm (1h)          IgG 2573 mg/dl
  Neu 52%                 150 mm (2h)              IgA 231 mg/dl
  Ly 9%                   CRP 2.9 mg/dl            IgM 277 mg/dl
  Mo 6%                                            IgE 143 IU/ml
  Eo 33%                                           
  Ba 0%                   **Arterial blood gas**   **Pulmonary function**
  RBC 417×10^4^/mm^3^     pH 7.444                 FVC 1.09 l
  Hb 9.3 g/dl             PaCO2 34.5 mmHg          %FVC 39.0%
  Plat 50.6×10^4^/mm^3^   PaO2 81.7 mmHg           DLCO 6.9 ml/min/mmHg

###### 

Laboratory data on recurrence to remission. A slight change in %FVC was observed over time. Determination of %FVC was performed using non-invasive spirometry and the %FCV value was used as an indicator of her condition.

  **Date (YYMMDD)**   **991029**   **991126**   **991216**   **000107**   **000112**   **000117**   **000128**   **000204**   **000218**
  ------------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------
  WBC/micro-L         5300                                   6200                                                9200         
  Eosinophil%         4.0                                    9.8                                                 10.9         
  1 h mm              21           10                        80           30                                                  
  2 h mm              56           26                        125          80                                                  
  FVC                 3.10         3.36         3.40         2.48         3.06         3.00         3.34         3.34         3.38
  %FVC%               101          109          111          81.0         101          98           109          109          110
  FEV1 L              3.02         3.06         3.34         2.48         3.02         2.96         3.32         3.26         3.36
  FEV1%               98.7         97.6         98.2         86.9         97.4         98.7         99.4         97.6         99.4
  V50 L/Min           5.25         5.58         5.01         4.75         5.17         4.73         5.89         4.72         5.34
  V25 L/Min           3.81         2,77         2.73         2.95         2.59         2.53         3.26         2.69         2.83
  PEF L/Min           6.09         7.24         7.86         6.35         6.92         6.78         7.44         7.57         7.87
  BDP 800 microg      800          800          800                                                                           
  Predonine mg/day                                           15           15           15           15           10           5
  Fluticasone                                                                                       800          800          800

FVC -- forced vital capacity; FEV1 -- forced expiratory volume/1 second; PEF -- peak expiratory flow L/min.

###### 

Eosinophilic pneumonia recurred 12 times despite various steroid inhalation therapies. To control the disease condition and to avoid adverse effects associated with systemic administration of steroids, we tried 5 different dosages of steroids through the inhalation route. The controller became single use of steroid inhalation therapy, but after several months, the eosinophilic pneumonia symptoms re-appeared.

  **Date (recurrence)**   **Diagnosis by**            **Before drug**                   **Added or changed drug**
  ----------------------- --------------------------- --------------------------------- ---------------------------------
  000117 (YYMMDD)         %FVC: 98%                   Fultide Discus 800 μg, Pred 5mg   Pred 10 mg
  000304                  %FVC: 105, Eo: 14.7%        Fultide Discus 800 μg             Pred 10 mg
  031215                  %FVC: 98%, BSR: 55 mm/1 h   Fultide Discus 800 μg             Pred 10 mg, Pulmicort T; 400 μg
  040331                  %FVC: 96%                   Pulmicort T 400 μg                Pred 10 mg
  040810                  %FVC: 98%, BSR 56: mm/1 h   Pulmicort T 400 μg                Pred 10 mg
  050223                  %FVC: 97%                   Fultide discus 40 0μg             Pred 10mg. Qvar 400 μg
  050621                  %FVC: 92%, BSR 91: mm/1 h   Qvar 200 μg                       Pred 10mg, Qvar 400 μg
  050824 no recurrence                                Qvar 400 μg                       Fultide air 200 μg
  060510                  %FVC: 91%                   Fultide air 200 μg                Pred 20 mg
  070621                  %FVC: 100%                  Fultide air 200 μg                Fultide Discus 600 μg
  090518                  BSR: 25 mm/1 h, Eo: 20%     Fultide discus 600 μg             Pred 20 mg
  100412                  %FVC: 96%                   Fultide discus 600 μg             Pred 20 mg, Palmicort S 1000 μg
  110225                  Chest-xp                    Pulmicort S 1000 μg               Transfer to hospital

BSR -- blood sedimentation rate; Pulmicort T -- pulmicort turbuhaler; Pulmicort S -- pulmicort suspension; Eo -- eosinophil % in peripheral blood.
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